Federal Research Center for Virology and Microbiology (FRCVM), Volginsky, Vladimir Region, Russia.
PLoS One. 2022 May 12;17(5):e0265819. doi: 10.1371/journal.pone.0265819. eCollection 2022.
The spread of African swine fever (ASF) in Eurasia has forced a return to the development of live vaccines based on naturally or experimentally attenuated strains of the virus including those resulting from genetic manipulations. This process includes evaluation of the immunomodulating properties of the vaccines. In this report we provide our assessment of two tests for immunobiological evaluation of a candidate live vaccine against ASF from the attenuated ASF virus (ASFV) strain KK-202: (i) investigation of the effect of the attenuated ASFV strain KK-202 on the protectiveness of the vaccine ASFV strain FK-32/135 and a vaccine against classical swine fever (CSF) from the strain LK-VNIIVViM; (ii) determination of the phagocytic activity of blood neutrophils in pigs inoculated with ASFV strains differing in virulence. A simultaneous or sequential inoculation of attenuated strain KK-202 (seroimmunotype II) and vaccine strain FK-32/135 (seroimmunotype IV) into pigs resulted in the loss of protection against the virulent strain France-32 (seroimmunotype IV). Following the simultaneous or sequential inoculations of the ASFV strain KK-202 and the CSF virus (CSFV) vaccine produced from the strain LK-VNIIVViM, the neutralizing antibody titers against the CSFV observed in the experimental groups (after vaccination and after the challenge infection with the virulent CSFV strain Shimen) were not different from those found in animals of the control group. The phagocytic activity of blood neutrophils was shown to increase from 30% in the norm to 50%-94% depending on the virulence of the ASFV strains inoculated into pigs. The results of this work demonstrate the ability of the attenuated ASFV strains to modulate the development of the cellular link of protective immunity without negative impact on the humoral immune response. The informative value of the described immunobiological tests in vivo and in vitro seems to be a more preferable alternative in comparison to the commonly used in vitro tests, which do not always correlate with the development of protection against ASF.
欧亚地区非洲猪瘟(ASF)的传播迫使人们重新开发基于自然或实验减毒病毒株的活疫苗,包括通过基因操作产生的病毒株。这个过程包括评估疫苗的免疫调节特性。在本报告中,我们对两种用于评估减毒 ASF 病毒(ASFV)株 KK-202 候选活疫苗的免疫生物学检测进行了评估:(i)研究减毒 ASFV 株 KK-202 对疫苗 ASFV 株 FK-32/135 和针对经典猪瘟(CSF)的疫苗株 LK-VNIIVViM 的保护作用的影响;(ii)确定接种不同毒力 ASFV 株的猪血液中性粒细胞的吞噬活性。同时或先后接种弱毒 KK-202 株(血清型 II)和疫苗株 FK-32/135 株(血清型 IV)会导致对强毒法国-32 株(血清型 IV)的保护力丧失。同时或先后接种 KK-202 株和 CSF 疫苗株(由 LK-VNIIVViM 株产生)后,实验组观察到的针对 CSF 病毒的中和抗体滴度(接种后和用强毒 CSF 株 Shimen 攻毒后)与对照组动物的抗体滴度无差异。血液中性粒细胞的吞噬活性从正常的 30%增加到 50%-94%,取决于接种到猪体内的 ASFV 株的毒力。这项工作的结果表明,弱毒 ASFV 株有能力调节保护性免疫的细胞性环节的发展,而不会对体液免疫反应产生负面影响。与通常不与 ASF 保护力发展相关的体外常用测试相比,体内和体外描述的免疫生物学测试的信息价值似乎是一种更可取的替代方法。